Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
NASA and SpaceX Target Crew-11 Undocking From ISS Amid Medical Concern 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure 
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Oil Prices Slip as U.S.–Iran Talks Ease Supply Disruption Fears 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
A South Korean research team has developed a strip-type urine test that successfully diagnoses prostate and pancreatic cancer on-site by amplifying the optical signal of the metabolome in urine.
The joint research team is from the Korea Institute of Materials Science, Pohang University of Science and Technology, and Kyung Hee University
The surface-enhanced Raman scattering sensor that they developed can amplify the optical signal of the metabolome in urine by more than 1 billion times by forming a coral reef-shaped plasmonic nanomaterial on top of porous paper material.
A light irradiation after a 10-microliter urine droplet amplified signal of cancer metabolome on the sensor’s surface without the need to go through a separate analysis process,.
The application of an artificial intelligence-based analytical method for the spectrum signal generated through the irradiation of light into the urine can identify people with prostate cancer and pancreatic cancer with an accuracy of up to 99 percent.
